UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 20, 2008
AVI BioPharma, Inc.
(Exact name of Company as specified in its charter)
|
Oregon |
|
001-14895 |
|
93-0797222 |
|
(State or other |
|
(Commission File No.) |
|
(I.R.S. Employer |
|
jurisdiction of |
|
|
|
Identification No.) |
|
incorporation) |
|
|
|
|
One S.W. Columbia, Suite 1105
Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On March 20, 2008, AVI BioPharma, Inc. (the “Company”) completed its acquisition of Ercole Biotech, Inc., a privately held Delaware corporation. A copy of the press release issued by the Company announcing the completion of the acquisition is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
|
|
|
|
|
|
|
|
|
|
The following exhibits are furnished herewith: |
|
|
|
|
|
|
|
|
|
|
|
99.1 |
Press Release dated March 24, 2008. |
|
|
2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on March 24, 2008.
|
|
AVI BioPharma, Inc. |
|
|
|
|
|
|
|
By: |
/s/ Alan P. Timmins |
|
|
|
|
|
|
|
Alan P. Timmins |
|
|
|
President and Chief Operating Officer |
3
Exhibit Index
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated March 24, 2008. |
4